We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+55.76%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$7B
AUM Growth
+$1.73B
Cap. Flow
-$39.7M
Cap. Flow %
-0.57%
Top 10 Hldgs %
37.61%
Holding
156
New
40
Increased
17
Reduced
34
Closed
20

Top Buys

Rank Stock Value
1
ETNB
89bio
ETNB
+$111M
2
BMY icon
Bristol-Myers Squibb
BMY
+$97.4M
3
GKOS icon
Glaukos
GKOS
+$94.2M
4
DHR icon
Danaher
DHR
+$91.1M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$77.7M

Top Sells

Rank Stock Value
1
AVDR
Avedro, Inc Common Stock
AVDR
+$96.3M
2
WMGI
Wright Medical Group Inc
WMGI
+$79.2M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$66.9M
4
TCDA
Tricida, Inc. Common Stock
TCDA
+$55.9M
5
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$45.8M

Sector Composition

Rank Sector Weight
1 Healthcare 97.72%
2 Financials 1.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$16.7B
$465M 6.64%
3,343,100
-376,073
-10% -$41.8M
THOR
2
DELISTED
Synthorx, Inc. Common Stock
THOR
$372M 5.3%
5,316,355
– –
TCDA
3
DELISTED
Tricida, Inc. Common Stock
TCDA
$363M 5.18%
9,614,280
-1,500,000
-13% -$55.9M
SWTX
4
DELISTED
SpringWorks Therapeutics
SWTX
$285M 4.07%
7,406,307
– –
PRVL
5
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$219M 3.12%
13,822,463
– –
BSX icon
6
Boston Scientific
BSX
$68.5B
$211M 3.02%
4,674,800
-593,900
-11% -$24.9M
ALEC icon
7
Alector
ALEC
$169M
$189M 2.7%
10,987,944
-1,544,385
-12% -$26.3M
ALXN
8
DELISTED
Alexion Pharmaceuticals
ALXN
$180M 2.57%
1,662,585
-700
-0% -$74.9K
MRK icon
9
Merck
MRK
$326B
$178M 2.54%
2,047,897
– –
MRTX
10
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$173M 2.47%
1,340,600
+805,457
+151% +$77.7M
VRTX icon
11
Vertex Pharmaceuticals
VRTX
$124B
$171M 2.45%
783,100
-63,300
-7% -$12.8M
TPTX
12
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$171M 2.44%
2,745,327
– –
IOVA icon
13
Iovance Biotherapeutics
IOVA
$2.1B
$154M 2.19%
5,548,326
– –
NXTC icon
14
NextCure
NXTC
$22.1M
$153M 2.18%
225,918
– –
HUM icon
15
Humana
HUM
$46.7B
$144M 2.05%
391,900
+210,100
+116% +$66.6M
BMY icon
16
Bristol-Myers Squibb
BMY
$130B
$109M 1.56%
+1,700,000
New +$97.4M
EHTH icon
17
eHealth
EHTH
$43.2M
$107M 1.53%
1,111,914
-5,500
-0.5% -$427K
ETNB
18
DELISTED
89bio
ETNB
$105M 1.5%
+4,004,442
New +$111M
EW icon
19
Edwards Lifesciences
EW
$48.2B
$101M 1.45%
1,304,700
-218,700
-14% -$17.1M
NBIX icon
20
Neurocrine Biosciences
NBIX
$18.4B
$101M 1.44%
935,970
-639,200
-41% -$66.9M
CI icon
21
Cigna
CI
$79.6B
$100M 1.43%
489,700
+198,100
+68% +$36.3M
INSP icon
22
Inspire Medical Systems
INSP
$1.5B
$100M 1.43%
1,347,000
-124,000
-8% -$7.97M
ARQL
23
DELISTED
Arqule Inc
ARQL
$99.8M 1.42%
5,000,000
+1,298,727
+35% +$15.1M
ISRG icon
24
Intuitive Surgical
ISRG
$130B
$99.2M 1.42%
503,400
-113,400
-18% -$21.2M
SRPT icon
25
Sarepta Therapeutics
SRPT
$1.63B
$98.9M 1.41%
766,049
-71,300
-9% -$7.2M
1
2 3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q4 2019 Portfolio in Review

As of Q4 2019, OrbiMed held 156 positions worth $7B, up 33% from $5.27B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

OrbiMed's Q4 2019 filing shows 40 new, 17 increased, 34 reduced and 20 closed positions. Its largest new stake was 89bio: 4,004,442 shares worth $105M. The largest sale was Avedro, Inc Common Stock, an estimated $96.3M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Financials.

  • OrbiMed's largest Q4 2019 buy was 89bio: 4,004,442 shares worth $105M.
  • OrbiMed added most to Mirati Therapeutics, Inc. Common Stock in Q4 2019, an estimated $77.7M increase.
  • OrbiMed's biggest Q4 2019 reduction was Neurocrine Biosciences, cutting an estimated $66.9M.
  • OrbiMed fully exited Avedro, Inc Common Stock in Q4 2019, selling an estimated $96.3M.
  • OrbiMed's ten largest holdings make up 38% of its $7B portfolio in Q4 2019.
  • OrbiMed opened 40 new positions and closed 20 in Q4 2019.
  • OrbiMed's portfolio value rose 33% quarter-over-quarter to $7B.

Based on OrbiMed's 13F filing for Q4 2019, filed 14 Feb 2020.